



HERBERT
SMITH
FREEHILLS



JIN KONG

SENIOR FOREIGN REGISTERED LAWYER (USA
- NEW YORK)

[Hong Kong](#)

Jin advises investment banks and corporate clients on capital markets transactions across Asia Pacific.

 +852 21014116

 Jin.Kong@hsf.com

 [linkedin.com/in/jin-kong-a332a214](https://www.linkedin.com/in/jin-kong-a332a214)

BACKGROUND

Jin is admitted to the New York State Bar. She is a graduate of the University of Illinois at Urbana-Champaign (J.D. and LL.M.) and the East China University of Political Science and Law (LL.B.).

Jin is a native Mandarin speaker and fluent in English.

KEY SERVICES

Capital Markets
US Securities

KEY SECTORS

Financial Institutions
Pharmaceuticals and Healthcare

EXPERIENCE

Jin has extensive experience of advising issuers, vendors and investment banks on equity and debt capital markets transactions including initial public offerings, private placements and rights issues, as well as investment grade, high yield and sovereign debt offerings under Rule 144A and Regulation S.

Jin's practice focuses on the Asia Pacific markets, particularly Greater China, Australia, India and Southeast Asia. Her title in Hong Kong is Senior Foreign Registered Lawyer (USA - New York) for local regulatory reasons.

Jin's recent experience includes:

- advising CICC and BofA Securities as joint sponsors of on-demand delivery service provider Hangzhou SF Intra-city Industrial Co., Ltd.'s HK\$2.15 billion listing on the Main Board of the Hong Kong Stock Exchange and Rule 144A/Regulation S global offering
- advising Morgan Stanley and J.P. Morgan as joint sponsors of biopharmaceutical company Abbisko Cayman Limited's HK\$1.75 billion listing on the Main Board of the Hong Kong Stock Exchange and Rule 144A/Regulation S global offering
- advising Morgan Stanley Asia Limited and Huatai Financial Holdings on medical device manufacturer Peijia Medical Limited's HK\$2.34 billion listing on the Main Board of the Hong Kong Stock Exchange and Rule 144A/Regulation S global offering
- advised Goldman Sachs and JP Morgan on biopharmaceutical company Antengene Corporation Limited's HK\$2.6 billion listing on the Main Board of the Hong Kong Stock Exchange and Rule 144A/Regulation S global offering
- advising Macquarie Capital Limited and China Merchants Securities (HK) on Cathay Media and Education Group Inc.'s HK\$1.24 billion listing on the Main Board of the Hong Kong Stock Exchange and Rule 144A/Regulation S global offering
- advising China Huaneng Group on (i) US\$1 billion Regulation S offering of guaranteed fixed rate notes in January 2021; (ii) US\$1 billion Regulation S offering of perpetual securities in December 2020; and (iii) US\$1.5 billion Regulation S offering of guaranteed fixed rate notes in December 2019, and Huaneng Power International on US\$600 million Regulation S offering of guaranteed fixed rate notes in February 2020, each listed on the Hong Kong Stock Exchange

© HERBERT SMITH FREEHILLS LLP 2022